Caligan Partners LP
CIK 1727492
13F filing for Q2 2026・No. 1,572
- Holdings
- US$2.13B
- Quarter change
- +US$622.94M
- Entries
- 28
- Net bought (estimate)
- +US$107.72M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 5
- Sold out 4
- Cut 3
- Added 10
- Corporate actions 0
- Unchanged 7
Largest holdings
25 stocks worth US$2.07B, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| LIQUIDIA CORPORATIONCOM NEW | Unchanged | 8,118,892 | US$647.32M | 31.23% |
| RVMDREVOLUTION MEDICINES INCCOM | Added | 1,961,795 | US$367.4M | 17.73% |
| ABIVAX SASPONSORED ADS | Added | 1,557,924 | US$207.61M | 10.02% |
| PCVXVAXCYTE INCCOM | Added | 2,188,636 | US$127.23M | 6.14% |
| EXELEXELIXIS INCCOM | Unchanged | 1,553,262 | US$84.51M | 4.08% |
| TANGO THERAPEUTICS INCCOM | Added | 2,500,103 | US$78.15M | 3.77% |
| AVALO THERAPEUTICS INCCOM NEW | Added | 3,163,866 | US$58.47M | 2.82% |
| XENEXENON PHARMACEUTICALS INCCOM | Cut | 889,944 | US$53.72M | 2.59% |
| ADMAADMA BIOLOGICS INCCOM | Added | 5,725,007 | US$47.92M | 2.31% |
| LB PHARMACEUTICALS INCCOM SHS | Unchanged | 1,438,070 | US$46.67M | 2.25% |
Sign in (free) to see its 25 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.